Trial Profile

A Phase 2 Randomized, Multicenter, Double-Blind Study of the Glutaminase Inhibitor Telaglenastat With Pembrolizumab and Chemotherapy Versus Placebo With Pembrolizumab and Chemotherapy in First-Line, Metastatic KEAP1/NRF2-Mutated, Nonsquamous, Non-Small Cell Lung Cancer (NSCLC)

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 25 Mar 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Telaglenastat (Primary) ; Carboplatin; Cobalamin; Dexamethasone; Folic acid; Pembrolizumab; Pemetrexed
Indications Non-small cell lung cancer
Focus Adverse reactions; Therapeutic Use
Acronyms KEAPSAKE
Sponsors Calithera Biosciences

05 Nov 2021 Interim results presented in a Calithera Biosciences media release.
05 Nov 2021 Status changed from active, no longer recruiting to discontinued due to lack of clinical benefit observed in patients treated with telaglenastat in an interim analysis, according to a Calithera Biosciences media release.
05 Nov 2021 Planned End Date changed from 1 Oct 2024 to 1 May 2022.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com